Alto Neuroscience appoints Andrew Miller to board; former Karuna Therapeutics president

Alto Neuroscience, Inc.

Andrew Miller, Ph.D., appointed to board effective May 27, 2026, filling vacancy after board size increased to seven.
Miller founded Karuna Therapeutics and served as President of R&D until its acquisition by Bristol Myers Squibb in March 2024.
Appointed to the Nominating and Corporate Governance Committee, replacing Christopher Nixon Cox.
Initial option grant for up to 48,200 shares (Black-Scholes value ≤$400k); annual retainer $40k plus $5k for NCGC service.
Board determined Miller is independent under NYSE and SEC rules.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew Miller

Director

ANRO · Alto Neuroscience, Inc.

Effective: 2026-05-27
Filed: May 28, 2026, 8:18 AM ET

the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Miller was appointed as Director at Alto Neuroscience, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.

View on SEC.gov

Alto Neuroscience, Inc. filing history →

Source: SEC EDGAR

accession 0001999480-26-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.